How We Recovered $50,000+ in Rheumatoid Arthritis Infusion Claims: A Real Billing Case Study

Rheumatoid Arthritis Infusion claims are one of the most denied types of claims in medical billing. Medications such as Remicade, Actemra, Orencia and Simponi Aria require regular appointments, including complex prior authorization restrictions and documentation requirements. Even a minor missed process can be a denied claim, a delayed payment or a lengthy appeal.

In this case study, we examine a true infusion practice that was experiencing a high denial rate in particular on Rheumatoid Arthritis Infusion denials. Rather than assuming that the root cause of the denials was due to a single cause, the billing team performed a comprehensive claims audit, segmented denials by reason and by particular payer, and corrected each root cause denial individually.

This blog details exactly why these claims are denied and how each of these issues was found and addressed. Each of the reasons for denial is immediately followed by the solution that resolved their issue so healthcare professionals and billing teams can cross-check their claims against these patterns and apply the same fixes if they are required.

 

Denial Reason: Missing or Expired Prior Authorization in Rheumatoid Arthritis Infusion Claims

The most frequent cause for Rheumatoid Arthritis Infusion claims to be rejected is a missing or expired prior authorization. The infusion drugs used to treat RA are administered periodically, usually every 4 to 8 weeks, so it is possible that the authorization will lapse and the patient won’t be aware of it until the claim is returned as denied.

The issue is even more problematic when a patient is rotated between different infusion medications, as each medication usually requires an individual authorization, rather than a general one.

Common triggers:

• Prior authorization expires mid infusion treatment cycle
• Front desk staff skips the auth check before the visit
• Auth request submitted far too close to visit date
• New infusion drug started without pulling a new auth

Solution:

• Verify authorization status 48 hours before the visit
• Track auth expiry dates against the treatment cycle
• Assign one staff member to handle all auth renewals
• Pull a fresh authorization for every drug change

Once this process was put in place, prior authorization related denials on Rheumatoid Arthritis Infusion claims dropped noticeably within the first month.

 

Denial Reason: Incorrect J-Code in Rheumatoid Arthritis Infusion Claims

Each of the Rheumatoid Arthritis Infusion drugs  has their own J-code and these codes change more frequently than most billing teams realize. Having the wrong code, the obsolete code or a code for a similar drug is quick to result in a denial.

This is a problem that can arise in larger practices, as multiple coders may be submitting infusion claims without having a unified and current infusion reference sheet.

Common triggers:

• Outdated J-code used for the infusion drug billed
• Coder is unfamiliar with newer HCPCS code updates
• Similar infusion drugs billed under the wrong J-code
• No shared, updated code sheet across the coding team

Solution:

• Use updated, drug specific J-code crosswalks always
• Train coders on RA infusion codes on a regular basis
• Review the full code list every single quarter
• Keep one shared reference sheet for all coders

 

Denial Reason: Wrong Units Billed in Rheumatoid Arthritis Infusion Claims

The payers update the J-code for these infusion drugs more often than most billing teams expect, and each has a unique J-code. If you use an incorrect code, outdated code or code for a similar drug, it is a quick way to get denied.

In larger practices, more than one coder working on infusion claims can have different reference sheets and encounter this issue.

Common triggers:

• Billed units do not match the documented dosage
• Vial size gets miscalculated into billing units
• Rounding errors occur during unit conversion
• Drug waste is not documented as a separate line

Solution:

• Use a dosage to billing unit conversion checklist
• Double check all units before final claim submission
• Match billed units against the physician’s order
• Document drug waste properly with the JW modifier

 

Denial Reason: Missing NDC Number in Rheumatoid Arthritis Infusion Claims

Many Rheumatoid Arthritis Infusion claims are denied because they do not have the National Drug Code (NDC), or only part of it, or because it is wrong. It is a small thing but payers see it as a hard requirement and it is very common for them to reject claims without a valid NDC without trying to correct the claim.

Common triggers:

• NDC field is left completely blank on claim form
• Wrong NDC number entered for the drug administered
• NDC not updated after a drug batch or lot change
• NDC format does not match the payer’s requirements

Solution:

• Add a mandatory NDC validation field in the EHR
• Validate every NDC before the claim is submitted
• Update NDC records immediately after batch changes
• Confirm NDC format matches each payer’s specs

 

Denial Reason: Medical Necessity Not Documented for Rheumatoid Arthritis Infusion

Payers frequently deny Rheumatoid Arthritis Infusion claims when medical necessity is not clearly documented in the patient’s chart. This usually happens when the diagnosis code on the claim is not directly and clearly connected to the reason infusion therapy was chosen over other treatment options.

Common triggers:

• Diagnosis code is not clearly linked to the therapy
• Missing lab results that support the diagnosis given
• Clinical notes copied over from a previous visit
• No documented record of prior treatments tried

Solution:

• Use templates that link diagnosis to infusion therapy
• Attach the most recent lab results with each claim
• Update clinical notes fully for every single visit
• Document all prior therapies that were already tried

 

Denial Reason: Incorrect Modifier Usage in Rheumatoid Arthritis Infusion Claims

Modifier errors are a hidden but common cause of denial in Rheumatoid Arthritis Infusion claims, especially when multiple drugs, infusion times, or services are billed together during the same visit. A missing or incorrect modifier can cause a payer to deny the entire line, not just part of it.

Common triggers:

• Modifier missing entirely on multi drug claims
• Wrong modifier used for the infusion site of care
• Modifier not updated to match current payer rules
• Same modifier reused incorrectly across all drugs

Solution:

• Keep a modifier reference guide for infusion services
• Run every claim through a scrubber tool first
• Review payer specific modifier rules regularly
• Assign correct modifiers based on each drug line

 

Denial Reason: Site of Care Mismatch in Rheumatoid Arthritis Infusion Claims

Rheumatoid Arthritis Infusion claims are sometimes denied simply because the site of care does not match what the payer expects or has approved for that specific patient plan. Many payers now prefer home infusion or outpatient settings over in office infusion for certain RA drugs, and billing the wrong site of care leads to an automatic denial.

Common triggers:

• Office visit billed when the payer prefers home care
• Outpatient infusion setting was not preauthorized
• Site of care does not match the payer’s policy
• Patient’s plan changed site of care rules mid year

Solution:

• Confirm the correct site of care before scheduling
• Check payer policy for each individual patient plan
• Update the POS code so it matches the approved site
• Recheck site of care rules at every plan renewal

Denial Reason: Timely Filing Limit Missed for Rheumatoid Arthritis Infusion Claims

Some Rheumatoid Arthritis Infusion claims are denied simply because they were filed after the payer’s deadline, even when everything else on the claim, including coding, units, and documentation, is completely correct. Once a filing deadline passes, most payers will not accept the claim at all, making this one of the most costly and hardest denials to reverse.

Common triggers:

• Completed claim sat unsubmitted past the deadline
• Resubmission delayed after the very first denial
• No tracking system in place for filing deadlines
• Corrected claims were not present within the window

Solution:

• Run weekly claim aging reports across all payers
• Flag every claim nearing its filing deadline early
• Assign a clear owner for late claim follow up work
• Resend corrected claims within just a few days

 

Results Summary

Once these problems were fixed and identified, the claim denials for Rheumatoid Arthritis went down considerably in just a few months. The team took a proactive approach to the denials and created a consistent workflow for prior authorization, coding, documentation and filing deadline.

Metric	Before	After
Denial rate	18 percent	6 percent
Denied claims recovered	$0	Over $50,000
Average days in accounts receivable	52 days	34 days
Weekly staff hours on denial rework	20 hours	10 hours
Appeal success rate	40 percent	75 percent
Claims needing manual resubmission	22 percent	9 percent

Rheumatoid Arthritis Infusion denials are clearly not an across-the-board mistake in billing, but can be prevented from payer to payer and drug to drug once the root cause is determined, as the results show. The low denial rate following the initial cleanup was maintained through a structured process, rather than a one-time solution.

 

Conclusion

Denials for Rheumatoid Arthritis Infusion claims are more than just a matter of generic billing fixes. It needs to be done as a single set process to review prior authorization timing, drug specific coding, documentation, modifiers, site of care, filing deadlines, etc. as one process and not one at a time when issues arise.

Infusion Billing Services focuses on Rheumatoid Arthritis Infusion billing and coding errors. With the goal of helping practices discover success and revenue loss patterns early on before it takes a toll on practice revenue and cash flow. If you are experiencing comparable denial patterns, you should contact our team for a denial audit today to see just just where your claims are being denied, and what it will take to get them through for the future.